All stock lists
Xencor Inc (NASDAQ:XNCR)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$38.13-$1.84 (-4.60%)
Market cap
$2.86B
Insider Score
Health Score
Analyst consensus
Listed since
Dec 3, 2013
Website
Insider Score
––Not scored
XNCR Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
XNCR analyst forecast
XNCR analyst consensus
Moderate Buy9 ratings
Buy 7 Hold 2 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
XNCR 12-month price target
$44.00+15.4% upsideaverage of 4 firms
$45.00High
$43.00Low
Best analysts covering XNCR
- Cantor Fitzgerald100%success rate · +155.4% avg return · 1 call
- Wedbush50%success rate · +54.1% avg return · 6 calls
- Wells Fargo50%success rate · +83.7% avg return · 2 calls
- Barclays50%success rate · +26.4% avg return · 2 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
XNCR analyst ratings
Filters
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Overweight | $44.00 | +114.6% | Reiterated | 2026-11-05 | |
| RBC Capital | Outperform | $43.00 | +47.4% | Reiterated | 2026-10-27 | |
| Wells Fargo | Overweight | $44.00 | +50.8% | Reiterated | 2026-10-27 | |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-10-27 |
| Wedbush | Outperform | $45.00 | +56.4% | Reiterated | 2026-10-27 | |
| — | B of A Securities | Neutral | — | — | Reiterated | 2026-09-21 |
| Barclays | Overweight | $23.00 | +61.4% | Reiterated | 2026-09-11 | |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-09-03 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2026-09-01 |
| Wedbush | Outperform | $26.00 | +255.2% | Reiterated | 2026-08-06 | |
| RBC Capital | Outperform | $18.00 | +30.2% | Reiterated | 2026-08-06 | |
| — | JP Morgan | Neutral | — | — | Downgraded | 2026-03-24 |
XNCR earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-25 | -$0.64 | -$0.09 | $30.0M | $28.2M |
| 2026-05-06 | -$0.65 | -$1.71 | $27.9M | $4.5M |
| 2026-08-05 | -$0.80 | -$0.29 | $18.9M | $51.2M |
| 2026-11-04 | -$0.33 | $0.50 | $63.0M | $116.5M |
| 2027-02-24Upcoming | -$0.79 | — | $29.2M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.